Clinical trials: Estrogen-receptor-positive Breast Cancer
HER2-negative Breast Cancer
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with…
- Trial name
- SERENA-3 (NCT04588298)
- Testing
- AZD9833
- Where
- 12 sites in Georgia, Mexico and 1 more
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer
- Trial name
- B-001 (NCT04571437)
- Testing
- Capecitabine, Letrozole 2.5mg
- Where
- Egypt
- Volunteers
- 204 people
- Sponsor
- Cairo University
Unresectable or Metastatic Breast Cancer
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion.
- Trial name
- NCT06167694
- Testing
- HRS-8080; Dalpiciclib Isethionate Tablets
- Where
- 2 sites in China
- Volunteers
- 146 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Breast Cancer
DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)
This is a single centre, open label, phase II clinical study consisting of two parts, each consisting of a different dose of the same intervention to investigate the efficacy of dexamethasone as an adjunct to endocrine therapy in…
- Trial name
- DEMETER (NCT07786051)
- Testing
- Dexamethasone (Oral)
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Breast Cancer
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer.
- Trial name
- NCT00759642
- Testing
- lapatinib
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer Female
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers.
- Trial name
- NCT03747042
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Texas Southwestern Medical Center
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom.
- Trial name
- NCT06450873
- Testing
- Coriolus Versicolor Extract, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
Reversing Therapy Resistance With Epigenetic-Immune Modification
The investigators propose a randomized two arm trial, using Simon's 2-stage design, in ER+ patients with therapy resistant breast cancer to test the optimal sequence and dosing of epigenetic immune priming in hormone therapy…
- Trial name
- NCT02395627
- Testing
- Tamoxifen, Vorinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Francisco
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-)
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07318805
- Testing
- PF-08032562, Fulvestrant, Cetuximab
- Where
- 13 sites in United States
- Volunteers
- 260 people
- Sponsor
- Pfizer
Arthralgia, Breast Cancer
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy
RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.
- Conditions
- Arthralgia, Breast Cancer, Pain
- Trial name
- NCT01385137
- Testing
- omega-3 fatty acid
- Where
- 292 sites in United States
- Volunteers
- 262 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
A Study of ZN-c5 in Participants With Breast Cancer
This is a Phase 1 open-label, multicenter study to evaluate biomarkers for ZN-c5 in subjects with breast cancer
- Trial name
- NCT04176757
- Testing
- ZN-c5
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Zeno Alpha Inc.
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01750073
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of Nebraska
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS.
- Conditions
- Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT02774681
- Testing
- Cognitive Assessment, Palbociclib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
ER-positive Her2-negative Early Breast Cancer
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer
The need/benefit of adjuvant chemotherapy could be negligible for a certain category of patient with newly diagnosed unilateral non metastatic breast cancer.
- Trial name
- OPTIGEN (NCT03080428)
- Testing
- Genomic test
- Sponsor
- UNICANCER
Breast Cancer
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Primary Objectives: Dose Escalation: To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of amcenestrant administered as monotherapy…
- Trial name
- AMEERA-1 (NCT03284957)
- Testing
- Amcenestrant, Palbociclib, Alpelisib
- Where
- 25 sites in United States, Belgium and 8 more
- Volunteers
- 136 people
- Sponsor
- Sanofi
Early Breast Cancer, Metabolic Health
Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy
This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy.
- Conditions
- Early Breast Cancer, Metabolic Health, Estrogen Receptor Positive Breast Cancer
- Trial name
- EMETA (NCT06623903)
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- Aarhus University Hospital
Arthralgia, Breast Cancer
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole.
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications
- Trial name
- NCT01573442
- Testing
- testosterone
- Where
- 529 sites in United States, Puerto Rico
- Volunteers
- 227 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn…
- Trial name
- NCT01009437
- Testing
- ritonavir, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
This is a first-in-man trial, in which BYL719 will be administered to adult patients with advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease has progressed despite standard therapy or for…
- Trial name
- NCT01219699
- Testing
- BYL719, Fulvestrant
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
The investigators will establish a platform at Dartmouth-Hitchcock Medical Center to generate novel models of estrogen receptor alpha-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which…
- Trial name
- NCT02752893
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dartmouth-Hitchcock Medical Center